JAK1 Inhibitor Zemprocitinib Hits Targets in Refractory RA

Zemprocitinib, a next-generation JAK1 inhibitor, may tame rheumatoid arthritis that does not respond to at least one biologic disease-modifying antirheumatic drug, a phase 3 clinical trial finds.
Medscape Medical News

source https://www.medscape.com/viewarticle/selective-jak1-inhibitor-zemprocitinib-hits-efficacy-targets-2026a1000iy3?src=rss